|
|
|
| Expression of IFN-γ and IL-4 in colorectal cancer and their relationship with clinical stage |
| FANG Xianlei1,2 ZENG Liping1,2 LI Na1 XIANG Sha2 WU Shihui2 LU Xiaomin2 ZHANG Chang1,2 Liang LU1 |
1.Department of Pathology, the First Affiliated Hospital of Hu′nan University of Medicine, Hu′nan Province, Huaihua 418000, China;
2.School of Medicine, Hu′nan University of Medicine, Hu′nan Province, Huaihua 418000, China |
|
|
|
Abstract Objective To investigate the expression of T helper (Th)1 cytokine interferon-γ (IFN-γ) and Th2 cytokine interleukin-4 (IL-4) in colorectal cancer tissues and explore its relationship with clinical stage. Methods The intestinal tissue samples of 61 patients with colorectal cancer admitted to the First Affiliated Hospital of Hu′nan University of Medicine from January 2016 to August 2018 were collected as colorectal cancer group. According to the clinical stage, they were devided into clinical stage Ⅰ (16 cases)， clinical stage Ⅱ (20 cases)， clinical stage Ⅲ (15 cases)， clinical stage Ⅳ (10 cases). In addition, 5 cases (20 cases in total) of paracancer tissues 10 cm away from the edge of the cancer tissues were collected as the control group. The immunohistochemistry was used to detect the expression of IFN-γ and IL-4 in tissues. Then the mean integrated optical density (MIOD) of the positive staining fraction of each group was analyzed, and the expression differences of IFN-γ and IL-4 among all groups were compared. Results The higher the tumor stage, the weaker the positive degree of IFN-γ expression. The higher the tumor stage, the stronger the IL-4 positive. IL-4 MIOD value in clinical stage Ⅳ colorectal cancer tissue was higher than that in clinical stageⅠ-Ⅲ and the control group, IL-4 MIOD values in the clinical stage Ⅱ-Ⅲ colorectal cancer tissue were higher than those in clinical stage Ⅰ and the control group, IL-4 MIOD value in the clinical stage Ⅰ colorectal cancer tissue was higher than that in the control group, and the differences were statistically significant (all P < 0.05). IFN-γ MIOD value in clinical stage Ⅳ colorectal cancer tissue was lower than that in the clinical stage Ⅰ-Ⅲ and the control group, IFN-γ MIOD value in the clinical stage Ⅲ colorectal cancer tissue was lower than that in the clinical stage Ⅰ-Ⅱ and the control group, IFN-γ MIOD value in the clinical Ⅱ colorectal cancer tissue was lower than that in the clinical stage Ⅰ and the control group, IFN-γ MIOD value in the clinical stage Ⅰ colorectal cancer tissue was lower than that in the control group, and the differences were statistically significant (all P < 0.05). Conclusion The expression of cytokine IFN-γ is decreased in colorectal cancer tissues, and the expression of IL-4 is increased, which are closely related to the clinical pathological stage of patients.
|
|
|
|
|
|
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Razi S，BaradaranNoveiry B，Keshavarz-Fathi M，et al. IL-17 and colorectal cancer：From carcinogenesis to treatment [J]. Cytokine，2019，116：7-12.
[3] Rager JE，Suh M，Chappell GA，et al. Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis [J]. Toxicol Lett，2019，305：40-50.
[4] Jinesh GG，Sambandam V，Vijayaraghavan S，et al. Molecular genetics and cellular events of K-Ras-driven tumorigenesis [J]. Oncogene，2018，37（7）：839-846.
[5] Kumar S，Saini RV，Mahindroo N. Recent advances in cancer immunology and immunology-based anticancer therapies [J]. Biomed Pharmacother，2017，96：1491-1500.
[6] Han HS，Shin JS，Song YR，et al. Immunostimulatory effects of polysaccharides isolated from young barley leaves （Hordeum vulgare L.） with dual activation of Th1 and Th2 in splenic T cells and cyclophosphamide-induced immunosuppressed mice [J]. Int J Biol Macromol，2020， 147：954-964.
[7] Safar HA，Mustafa AS，Amoudy HA，et al. The effect of adjuvants and delivery systems on Th1，Th2，Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific proteins [J]. PLoS One，2020，15（2）：e0228381.
[8] Lin W，Niu Z，Zhang H，et al. Imbalance of Th1/Th2 and Th17/Treg during the development of uterine cervical cancer [J]. Int J Clin Exp Pathol，2019，12（9）：3604-3612.
[9] Zhao X，Liu J，Ge S，et al. Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance [J]. Front Pharmacol，2019，10：624.
[10] Lee HL，Jang JW，Lee SW，et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization [J]. Sci Rep，2019，9（1）：3260.
[11] Kaur RP，Vasudeva K，Singla H，et al. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer [J]. J Cell Physiol，2018，233（12）：9716-9723.
[12] Chen F，Li X，Wang J，et al. Combination of Ginsenoside H dripping pills and cyclophosphamide improve paraneoplastic syndrome and inhibit postoperative recurrence via the reversion of Th1/Th2 shift [J]. Biomed Pharmacother，2018，108：865-875.
[13] 王琰，卢斌峰，蒋敬庭.肿瘤浸润淋巴细胞及其亚群在肿瘤免疫中的作用[J].临床检验杂志，2018，36（11）：854-857.
[14] Witonsky S，Buechner-Maxwell V，Santonastasto A，et al. Can levamisole upregulate the equine cell-mediated macrophage（M1）dendritic cell（DC1）T-helper 1（CD4 Th1）T-cytotoxic（CD8）immune response in vitro? [J]. J Vet Intern Med，2019，33（2）：889-896.
[15] Walker JA，McKenzie ANJ. TH2 cell development and function [J]. Nat Rev Immunol，2018，18（2）：121-133.
[16] Gonzalez-Gugel E，Saxena M，Bhardwaj N. Modulation of innate immunity in the tumor microenvironment [J]. Cancer Immunol Immunother，2016，65（10）：1261-1268.
[17] Wang CY，Ding HZ，Tang X，et al. Comparative analysis of immune function，hemorheological alterations and prognosis in colorectal cancer patients with different traditional Chinese medicine syndromes [J]. Cancer Biomark，2018，21（3）：701-710.
[18] Tosolini M，Kirilovsky A，Mlecnik B，et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells（Th1，Th2，Treg，Th17）in patients with colorectal cancer [J]. Cancer Res，2011，71（4）：1263-1271.
[19] 王静，徐向上，曹志新，等.Th细胞因子在结直肠癌组织中的表达[J].中华实验外科杂志，2010（1）：62-64.
[20] 黄家豪，曹云飞，高枫.结直肠癌患者外周血Th1和Th2细胞的检测与临床意义[J].结直肠肛门外科，2012，18（2）：71-79. |
|
|
|
